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incomplete resection remains questionable. If GTR cannot be safely achieved, biopsy only might be used
as an alternative surgical strategy.
DOI: 10.1093/annonc/mdt388
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-85420
Accepted Version
Originally published at:
Kreth, F W; Thon, N; Simon, M; Westphal, M; Schackert, G; Nikkhah, G; Hentschel, B; Reifenberger,
G; Pietsch, T; Weller, M; Tonn, J C (2013). Gross total but not incomplete resection of glioblas-
toma prolongs survival in the era of radiochemotherapy. Annals of Oncology, 24(12):3117-3123. DOI:
10.1093/annonc/mdt388
Kreth et al., Submission Annals of Oncology 
 1 
Article type: Original Article, Clinical study 
Title: Gross total but not incomplete resection of GBM prolongs survival in the era of 
radiochemotherapy 
Running title:  Extent of resection and MGMT promoter methylation in glioblastoma 
Authors: F.-W. Kreth1*, N. Thon1*, M. Simon2, M. Westphal3, G. Schackert4, G. Nikkhah5, 
B. Hentschel6, G. Reifenberger7, T. Pietsch8, M. Weller9, and J.-C. Tonn1, for the German 
Glioma Network;  
*contributed equally 
Affiliations: 1Department of Neurosurgery, University of Munich LMU, Campus 
Großhadern, Munich, Germany; 2Department of Neurosurgery, University of Bonn Medical 
Center, Bonn, Germany; 3Department of Neurological Surgery, University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany; 4Department of Neurosurgery, Technical 
University of Dresden, Dresden, Germany; 5Department of Stereotactic Neurosurgery, 
University of Freiburg, Freiburg, Germany;  6Institute for Medical Informatics, Statistics and 
Epidemiology, University of Leipzig, Leipzig, Germany; 7Department of Neuropathology, 
Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; 8Institute of 
Neuropathology, University of Bonn Medical Center, Bonn, Germany; 9Department of 
Neurology, University Hospital Zurich, Zurich, Switzerland. 
Corresponding author: Professor Dr. Joerg-Christian Tonn, Department of Neurosurgery, 
University of Munich LMU, Campus Großhadern, Marchioninistrasse 15, D- 81377 Munich; 
Phone: ++49 (0) 89 7095-2591; Fax: ++49 (0) 89 7095-2592; E-mail: 
joerg.christian.tonn@med.uni-muenchen.de 
Counts: Number of characters: Title: 94/ Running Head: 65 // Number of words: 
Abstract: 244 / Manuscript: 2110 // Numbers of References: 22 // Numbers of figures / 
tables in main manuscript: 2 / 3. Number of supplement figures/ tables: 2/1 
Kreth et al., Submission Annals of Oncology 
 2 
Abstract 
Background: This prospective multicenter study assessed the prognostic influence of extent 
of resection as compared to biopsy only in a contemporary patient population with newly 
diagnosed glioblastoma. 
Patients and methods: Histology, O6-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation status and clinical data were centrally analysed. Survival analyses were 
performed with the Kaplan-Meier method. Prognostic factors were assessed with proportional 
hazards models. 
Results: Of 345 patients, 273 underwent open tumor resection and 72 biopsies; 125 patients 
had gross total resections (GTR) and 148 patients incomplete resections. Surgery-related 
morbidity was lower after biopsy (1.4% vs. 12.1%, p=0.007). 64.3% of patients received 
radiotherapy (RT) plus chemotherapy (CT), 20.0 % RT alone, 4.3% CT alone, and 11.3% 
best supportive care as initial treatment. Patients ≤ 60years and with a Karnofsky 
performance score (KPS) ≥ 90 were more likely to receive RT plus CT (p<0.01). Median OS 
(PFS) ranged from 33.2 months (15.0 months) for patients with MGMT methylated tumors 
after GTR and RT plus CT to 3.0 months (2.4 months) for biopsied patients receiving 
supportive care only. Favorable prognostic factors in multivariate analysis for OS were age ≤ 
60 years (HR=0.52; p<0.001), preoperative KPS ≥ 80 (HR=0.55; p<0.001), GTR (HR=0.60; 
p=0.003), MGMT promoter methylation (HR=0.44; p<0.001), and RT plus CT (HR=0.18, 
p<0.001); patients undergoing incomplete resection did not better than those receiving biopsy 
only (HR=0.85; p=0.31).  
Conclusions: The value of incomplete resection remains questionable. If GTR 
cannot be safely achieved, biopsy only might be used as an alternative surgical 
strategy.  
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Abbreviations  
CT, chemotherapy; EOR, extent of resection; GTR, gross total resection; HR, hazard ratio; 
KPS, Karnofsky performance score; MGMT, O6 methylguanine-DNA methyltransferase; 
MSP, methylation-specific PCR; OS, overall survival; PFS, progression-free survival; RT, 
radiotherapy, TMZ, temozolomide; WHO, World Health Organization 
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Introduction 
Glioblastoma is the most frequent and most aggressive primary brain tumor in adults [1]. 
Combined radio- and chemotherapy (RT plus CT) has become the standard of care [2] and 
has significantly improved the prognosis particularly for tumors exhibiting a methylated 
promoter of the gene encoding O6-methylguanine-DNA methyltransferase (MGMT) [3]. 
Gross total resection (GTR) before adjuvant treatment has also been shown to gain favorable 
impact on outcome [4-6]. In contrast, the prognostic place of incomplete resection as 
compared to biopsy only is not yet clearly defined [2]. The elucidation of this question is 
important since GTR cannot be always achieved [7, 8]. 
This multicenter observational study was conducted to identify prognostic factors in 
glioblastoma patients treated according to current standards of care. Based on our previous 
analysis on non-resectable glioblastomas demonstrating surprisingly long survival after 
biopsy only in the era of RT plus CT [9], we awaited similar survival rates after incomplete 
resection and biopsy only.  
 
Patients and Methods 
Study Design 
The German Glioma Network (GGN) has generated a prospective longitudinal database to 
follow patients with newly diagnosed glioblastoma. Patients were recruited from October 
2004 until March 2009; data base closure was March 2012. All patients gave informed 
consent. Data collection at enrolment and follow-up addressed important patient-, tumor-, and 
treatment-related parameters including MGMT promoter methylation status. The extent of 
open resection (EOR) was determined locally by early (<72 h) postoperative MRI and scored 
according to the study of Stummer et al. either as GTR (no residual contrast enhancement in 
T1-weighted sequences) or incomplete resection (any contrast-enhancement with a volume of 
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more than one voxel in the T1-weighted images) [10]. Prospective estimations of EOR were 
done in a blinded fashion. No additional volumetric analyses were performed. Central 
histological review according to the World Health Organization (WHO) [1] was done at the 
Department of Neuropathology, University of Bonn. Central determination of the MGMT 
promoter methylation status by methylation-specific PCR [3] was performed at the 
Department of Neuropathology, Heinrich Heine University Düsseldorf. Data were centrally 
collected and analysed (Institute for Medical Informatics, Statistics and Epidemiology 
(IMISE), University of Leipzig). Treatment decisions were independently rendered at each 
academic center. Tumor progression was assessed according to the Macdonald criteria [11]. 
 
Statistical analysis 
Associations of clinical data were tested by χ² test, Fisher’s exact test, and Mann-Whitney-U 
test. Suvival data were analyzed with the Kaplan-Meier method. Reference point was the date 
of first surgery. The log-rank test was used to compare outcome data. Multivariate analysis 
was performed with Cox regression models. p values ≤ 0.05 were considered as statistically 
significant. Statistical analyses were performed using IBM SPSS (Version 20.0.0).  
 
Results 
A total of 345 patients were analysed. Clinical data of the study population are summarized in 
Table 1. Sixty-two patients were older than 70 years and 28 patients had a Karnofsky 
performance score (KPS) below 70. GTR, incomplete resection, and biopsy were done in 125 
patients, 148 patients, and 72 patients, respectively. Biopsied patients were older (median: 65 
vs. 60 years; p=0.008), rated similarly on the performance scale (median KPS: 80 each, 
p=0.5), and had similarly often an eloquent tumor location (23.6% versus 19.4%; p=0.4) as 
compared to patients undergoing incomplete resection. The frequency of an eloquent tumor 
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location was lowest in the GTR-group (14.4%; p=0.04). Transient complication occurred in 
33 patients after resection and in one patient after biopsy (p=0.007). Histopathological 
diagnosis revealed 329 glioblastomas, 9 giant cell glioblastomas, and 7 gliosarcomas. A 
methylated MGMT promoter was found in 48.1% of the study cohort. Methylated and 
unmethylated tumors did not differ in terms of age (median: 60 vs. 62 years; p=0.4), KPS 
(median: 80 each, p=0.3), EOR (p=0.8), or mode of first-line treatment (p=0.8).  
 64.3% of the study population patients underwent RT plus CT. RT alone, CT alone, and 
supportive treatment were applied in 20.0%, 4.3%, and 11.3%, respectively. Patients ≤ 60 
years (odds ratio 3.3, 95%-CI 2.1-5.3) and patients with KPS ≥ 90 (odds ratio 3.0, 95%-CI 
1.8-4.8) were more likely to receive RT plus CT. Biopsied patients were less frequently 
treated with RT plus CT (odds ratio 0.5, 95% CI 0.3-0.8) and received more often supportive 
care only (odds ratio 2.4, 95% CI 1.2-4.9).  
 
Treatment results and prognostic/predictive factors 
Overall, 327 patients suffered from tumor progression and 310 patients deceased during the 
follow-up period. Median PFS was 6.4 months and median OS was 12.8 months. Outcome 
stratified for EOR as compared to biopsy, first-line treatment, and MGMT methylation status 
is given in Table 2: Outcome was best in case of RT plus CT (median PFS: 7.8 months/ 
median OS: 17.1 months) and worst after supportive treatment (median PFS: 2.7 months/ 
median OS: 3.0 months; supplement Figure S1). GTR was associated with superior OS 
(median: 17.1 months; p=0.001); OS after incomplete resection was not better than after 
biopsy only (median: 11.7 vs. 8.7 months; p=0.1; Figure 1). PFS was not influenced by EOR 
as compared to biopsy only. MGMT promoter methylation was associated with superior PFS 
(median: 7.6 vs. 5.8 months) and OS (median: 21.0 vs. 11.0 months) (each p<0.001; Figure 
1). 
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Subgroup analysis of patients after RT plus CT (N=222) revealed similar results (Figure 2): 
GTR was associated with prolonged OS (median: 21.0 months; p=0.034) whereas OS after 
incomplete resection and biopsy was similar (median: 15.2 vs. 15.7 months; p=0.4). Survival 
was best in MGMT methylated tumors undergoing GTR (median PFS: 15.0 months/ median 
OS: 33.2 months). Median PFS (OS) of biopsied, methylated tumors was 12.0 (26.2) months, 
which compared favorably with that of unmethylated tumors after GTR (5.7 (14.4) months; 
Table 2; supplement Figure S2).  
 
Cox models 
One-variable models are given in supplement Tables S1. Multivariate Cox regression 
analyses of both the overall population and the subpopulation receiving RT plus CT revealed 
similar results: Favorable prognostic factors for OS were age ≤ 60 years, KPS ≥ 80, GTR, 
MGMT promoter methylation, and RT plus CT; incomplete resection was not better than 
biopsy (Table 3). 
 
Discussion  
The highly invasive growth characteristics of glioblastomas explain that curative surgical 
treatment cannot be achieved [1]. Nevertheless, beneficial cytoreductive effects of GTR have 
been reported, which is defined as complete resection of the contrast-enhancing tumor parts 
[6, 12, 13]. According to more recently published prospective randomized data, GTR can be 
expected to be achieved in 40% of glioblastoma patients  [14]. The majority of glioblastoma 
patients still undergo incomplete resection and some of them receive biopsy only, which is 
due to diffuse tumor extension, affection of functional relevant areas, patient-related risk 
factors (such as increased age and co-morbidity), or any combination of these factors [9, 15]. 
Surprisingly, the prognostic impact of incomplete resection as compared to biopsy only 
Kreth et al., Submission Annals of Oncology 
 8 
remains unclear. The traditional view is that GTR is better than incomplete resection and the 
latter better than biopsy [2, 16]. A few studies, however, that have addressed this issue, did 
not analyze EOR by early postoperative MRI, did not control for the effect of MGMT 
promoter methylation and applied treatment strategies, and/or were seriously biased due to 
the influence of other prognostic factors (in favor of the resection group) [16, 17]. The 
current prospective observational study, which analyzed outcome measurements of a large 
and unselected patient population collected in six academic centers with a dedicated focus on 
neuro-oncology, goes one step beyond these limitations: Outcome measurements were 
adjusted for the effects of MGMT promoter methylation and other important patient-, tumor-, 
and treatment related factors. Patients undergoing biopsy only were used as a reference group 
for prognostic evaluation of open tumor resection. This approach overcomes selection bias, 
which always occurs when comparing surgery responders (GTR) with non-responders 
(incomplete resection) [18]. It was remarkable that the pre-treatment prognostic profile of the 
biopsy and the incomplete resection groups was not as different as usually found [16, 17]: 
Patients of the biopsy group were only slightly older, did not rate worse on the KPS scale and 
did not exhibit higher frequencies of eloquent tumor locations than those undergoing 
incomplete resection. Hence, patients in these two groups were relatively well balanced. It 
was noteworthy, however, that biopsied patients were less likely to receive RT or RT plus CT 
in this series. 
In accordance with other data we found GTR to prolong OS [5, 6, 12, 16]. A prognostic 
impact of incomplete resection, however, could not be detected: Incomplete resection did not 
provide advantages with respect to OS as compared to biopsy alone. This was demonstrated 
in both the full analysis and the subgroup analysis set of patients treated with RT plus CT. 
The latter analysis was performed to account for the described treatment related imbalances 
in the full analysis set: still existing but not significant differences in OS between biopsied 
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and incompletely resected patients in the full analysis set resolved nearly completely in the 
subgroup analysis.  
Beyond RT plus CT, MGMT promoter methylation turned out to be the most powerful factor 
influencing OS. Outcome in biopsied, MGMT methylated tumors was better than in tumors 
lacking MGMT promoter methylation after GTR and RT plus CT. The study results 
confirmed previously reported surprisingly long OS of biopsied GBM patients after 
combined treatment in case of a methylated MGMT promoter [9]. Apparently, tumors’ 
biology by far outweights the prognostic impact of resective surgery. The prognostic models 
did not indicate interactions between the influence of EOR as compared to biopsy and MGMT 
promoter methylation status. Surgery was not more effective in unmethylated or methylated 
tumors.  
EOR was dichotomized in the current report: Those exhibiting any gadolinium enhanced 
volume on their early post-operative MRI were classified as incomplete resection. The 
chosen classification scheme is supported by the results of the post-hoc evaluation of the 
prospective randomized data by Stummer et al. [6]: no distinct survival rates were found for 
subgroups undergoing different degrees of EOR; only those receiving GTR did significantly 
better. Since we considered these data as the currently most convincing ones for prognostic 
evaluation of EOR, the current study protocol was designed accordingly.  
Retrospective comparison of tumor size pre- and post-operatively has proposed a linear 
increase between EOR and survival beyond a threshold of approximately 78% in one more 
recently pusblished study [19]. The authors, however, have described overlapping 
subpopulations regarding EOR (>78%, >80%, >90% etc.) and it remains therefore unclear to 
which extent the applied top-down threshold calculation has been biased by those undergoing 
complete or nearly complete resection. Our data did not support those assumptions: For those 
undergoing RT plus CT, the prognostic impact of GTR was only moderate as compared to 
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biopsy only. Thus, the existence of true prognostic relevant thresholds in addition to GTR 
seems to be unlikely. The provided prognostic models of this study rather indicate non-linear 
correlations between EOR and outcome. 
The proponents of linear correlations between EOR and outcome are confronted with so far 
unresolved methodological problems: A proper identification of thresholds in addition to 
GTR demands non-overlapping subgroups exhibiting distinct degrees of EOR. Thus, large 
multi-institutional studies are necessary to analyze the interesting idea of a resection 
threshold for glioblastoma patients. Additionally, volumetric estimation of post-surgical MRI 
scans has been shown to suffer from low inter-observer agreement [20, 21].  
Apparently two different classes of glioblastoma patients exist: Those harboring resectable 
tumors (which should be resected) and those harboring unresectable ones, which do not need 
partial “debulking” unless decompressive surgery of pronounced and symptomatic space 
occupying lesions is necessary [22]. This conclusion is important for the patient and the 
treating oncologist: Surgery-related complications of potentally superfluous incomplete 
resection might delay the initiation of adjuvant treatment, decrease quality of life, and 
comprise outcome [7, 15]. Even though in the current series, the complication rate after open 
tumor resection was in the lower range of reported data in the literature [15], it was still ten-
times higher than after biopsy.  
We did not find any prognostic impact of open tumor resection on PFS. Estimation of PFS, 
however, might be biased in unfavor of the resection group particularly in case of GTR, as 
usually the appearance of any new lesion after GTR is classified as tumor recurrence; in 
contrast, a 25% increase of tumor volume is required for indication of tumor progression after 
incomplete resection or biopsy [11].  
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In summary, we found a moderate favorable prognostic effect of GTR in the era of RT plus 
CT. The efficacy of GTR was not influenced of MGMT promoter methylation, which turned 
out to be the most powerful pre-treatment factor for OS and PFS. In contrast, the prognostic 
value of incomplete resection as compared to biopsy only remains questionable. The 
indication of biopsy should be reconsidered for unresectable tumors, as biopsy can be safely 
performed and enables adequate histological diagnosis and determination of the MGMT 
promoter methylation status even in patients e. g. with eloquent tumors.  
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Figure legends: 
 
Figure 1: (A) PFS and (B) OS by extent of resection of the overall population. (C) PFS and 
(D) OS by MGMT promoter methylation status of the overall population. (IR, incomplete 
resection; GTR, gross total resection)  
 
Figure 2: (A) PFS and (B) OS by extent of resection for the RT plus CT subpopulation. (C) 
PFS and (D) OS by MGMT promoter methylation status for the RT plus CT subpopulation. 
(CT, chemotherapy; GTR, gross total resection; IR, incomplete resection; RT, radiotherapy) 
 
Figure S1: (A) PFS and (B) OS by treatment for the overall population. (CT, chemotherapy, 
RT, radiotherapy) 
 
Figure S2: (A) PFS and (B) OS by both extent of resection and MGMT promoter methylation 
status for the overall population. (GTR, gross total resection; IR, incomplete resection) 
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Supplement Table S1: Univariate analyses for the overall population 
PFS 
 Hazard ratio 95% CI p value 
Age  ≤ 60 vs. > 60   0.56 0.45-0.70 <0.001 
KPS ≥ 80 vs. < 80 0.67 0.51-0.87 0.002 
MGMT meth. vs. unmeth. 0.56 0.44-0.67 <0.001 
Extent of resection 
IR vs. biopsy (ref.) 
GTR vs. biopsy (ref.) 
 
0.88 
0.73 
 
0.66-1.12 
0.54-0.99 
 
0.410 
0.045 
Treatment 
RT or CT vs. pall. (ref.) 
RT plus CT vs. pall. (ref.) 
 
0.27 
0.17 
 
0.18-0.40 
0.12-0.25 
 
<0.001 
<0.001 
OS 
 Hazard ratio 95% CI p value 
Age  ≤ 60 vs. > 60   0.47 0.37-0.59 <0.001 
KPS ≥ 80 vs. < 80 0.53 0.41-0.70 <0.001 
MGMT meth. vs. unmeth. 0.43 0.34-0.55 <0.001 
Extent of resection 
IR vs. biopsy (ref.) 
GTR vs. biopsy (ref.) 
 
0.77 
0.55 
 
0.57-1.04 
0.40-0.75 
 
0.090 
<0.001 
Treatment 
RT or CT vs. pall. (ref.) 
RT plus CT vs. pall. (ref.) 
 
0.30 
0.15 
 
0.20-0.45 
0.11-0.22 
 
<0.001 
<0.001 
Legend: CT, chemotherapy; GTR, gross total resection; IR, incomplete resection; 
KPS, Karnofsky performance score; MGMT, O6-methylguanine-DNA 
methyltransferase; meth., methylated promoter status; unmeth, unmethylated 
promoter status; pall., palliative care; RT, radiotherapy, vs., versus 
 
Table 1. Summary of patients’ characteristics. 
 All patients (N=345)  
Age at diagnosis (years)   
Median 61  
Range 19-86  
Age classes N % 
  ≤50 years 85 24.6 
  51-60 years 83 24.1 
  61-70 years 115 33.3 
  >70 years 62 18.0 
Gender N  
  Male 209 60.6 
  Female 136 39.4 
KPS N % 
  90-100 146 43.2 
  70-80 164 48.5 
  <70 28 8.3 
  No data 7 - 
Surgery N % 
  Gross total resection 125 36.2 
  Incomplete resection 148 42.9 
  Biopsy 72 20.9 
Review diagnosis N % 
  Glioblastoma 329 95.4 
  Giant cell glioblastoma 9 2.6 
  Gliosarcoma 7 2.0 
MGMT promoter methylation status  N % 
  Methylated 163 48.1 
  Unmethylated 176 51.9 
  Unknown 6 - 
Therapy N % 
  First-line   
   Supportive care 39 11.3 
   RT alone 69 20.0 
   CT alone1 15 4.3 
   RT plus CT2 222 64.3 
  Second-line (N=161)   
   Surgery alone 26 16.1 
   Surgery plus CT 44 27.3 
   Surgery plus RT plus CT 9 5.6 
   RT alone 2 1.2 
  RT plus CT 21 13.0 
   CT alone 59 36.6 
Legend: CT, alkylating chemotherapy; RT, radiation therapy; 1, TMZ 
(N=13) or nitrosourea (N=2); 2, concomitant plus adjuvant TMZ 
(N=164), concomitant TMZ only (N=42), adjuvant TMZ only 
(N=12), nitrosourea (N=4), one dose was sufficient to place a patient 
in this group, non-alkylating agents were excluded, no patient 
received first-line bevacizumab. 
 
Table 2: Outcome of patients stratified for extent of resection, MGMT promoter methylation 
status and treatment regimes. 
 All patients Gross total resection Incomplete resection Biopsy 
PFS Median (95%CI) Event Median (95%CI) Event Median (95%CI) Event Median (95%CI) Event 
Palliative care 2.7 (1.0-3.5) 36/39 0.7 (0.4-1.0) 8/8 2.2 (0.9-3.5) 17/17 2.4 (1.3-3.4) 11/14 
RT alone 6.6 (5.9-7.3) 67/69 6.7 (5.8-7.5) 23/24 6.8 (5.3-8.2) 33/33 4.5 (2.3-6.6) 11/12 
CT alone 2.4 (1.3-3.5) 14/15 - 1/1 - 4/4 2.9 (0.02-5.8) 9/10 
RT plus CT 7.8 (6.6-9.0) 210/222 7.8 (4.8-10.8) 88/92 7.4 (6.2-8.5) 91/94 8.8 (4.3-13.4) 31/36 
Total 6.4 (5.7-7.1) 327/345 6.7 (5.7-7.7) 120/125 6.5 (5.7-7.3) 145/148 4.6 (3.1-6.0) 62/72 
Patients with MGMT promoter methylation 
Palliative care 1.7 (0.5-3.0) 17/18 - 4/4 2.3 (2.0-2.7) 7/7 - 6/7 
RT alone 5.4 (2.9-7.9) 28/30 5.1 (3.5-6.6) 10/11 7.5 (6.6-8.4) 15/15 - 3/4 
CT alone 2.9 (0.8-5.0) 8/9 - 0/0 - 0/0 2.9 (0.8-5.0) 8/9 
RT plus CT 13.2 (9.8-16.6) 97/106 15.0 (12.3-17.7) 41/45 9.0 (3.7-14.3) 44/46 12.0 (8.7-15.2) 12/15 
Total 7.6 (6.0-9.1) 150/163 10.2 (1.8-18.6) 55/60 7.6 (6.3-8.8) 66/68 4.1 (0.6-7.6) 29/35 
Patients without MGMT promoter methylation 
Palliative care 3.0 (0.2-5.8) 19/21 - 4/4 - 10/10 - 5/7 
RT alone 6.6 (5.3-7.8) 36/36 7.3 (5.3-9.3) 11/11 6.2 (6.0-6.4) 18/18 - 7/7 
CT alone - 6/6 - 1/1 - 4/4 - 1/1 
RT plus CT 6.4 (5.5-7.3) 110/113 5.7 (4.5-6.9) 46/46 6.8 (6.3-7.3) 47/48 7.3 (1.7-12.9) 17/19 
Total 5.8 (5.0-6.6) 171/176 6.4 (5.2-7.5) 62/62 6.1 (4.8-7.5) 79/80 4.7 (3.9-5.4) 30/34 
         
OS Median (95%CI) Event Median (95%CI) Event 
Median 
(95%CI) Event/n Median (95%CI) Event 
Palliative care 3.0 (1.4-4.6) 36/39 0.9 (0-4.8) 8/8 2.4 (0-4.9) 17/17 3.0 (0.6-5.5) 11/14 
RT alone 9.6 (8.4-10.8) 65/69 12.4 (4.2-20.5) 22/24 8.8 (7.1-10.6) 32/33 4.7 (3.5-6.0) 11/12 
CT alone 6.2 (3.4-9.0) 15/15 - 1/1 - 4/4 6.2 (2.3-10.1) 10/10 
RT plus CT 17.1 (14.5-19.6) 194/222 21.0 (18.9-23.1) 81/92 15.2 (11.8-18.4) 83/94 15.7 (10.1-21.3) 30/36 
Total 12.8 (11.2-14.4) 310/345 17.1 (12.6-21.5) 112/125 11.7 (10.0-13.5) 136/148 8.7 (6.3-11.2) 62/72 
Patients with MGMT promoter methylation 
Palliative care 2.3 (1.5-3.2) 17/18 - 4/4 - 7/7 - 6/7 
RT alone 9.9 (8.5-11.3) 27/30 9.6 (6.9-12.4) 9/11 10.1 (5.9-14.2) 15/15 - 3/4 
CT alone 6.2 (0.1-12.4) 9/9 - 0/0 - 0/0 6.2 (0.1-12.4) 9/9 
RT plus CT 27.5 (22.4-32.6) 83/106 33.2 (17.6-48.9) 35/45 24.4 (19.2-29.6) 37/46 26.2 (17.7-34.6) 11/15 
Total 21.0 (15.9-26.1) 136/163 25.2 (18.3-32.1) 48/60 17.9 (8.1-27.8) 59/68 11.6 (3.6-19.6) 29/35 
Patients without MGMT promoter methylation 
Palliative care 3.4 (1.6-5.1) 19/21 - 4/4 0.8 (0.1-1.6) 10/10 - 5/7 
RT alone 8.7 (8.0-9.5) 35/36 16.9 (9.0-24.7) 11/11 7.1 (3.3-10.9) 17/18 - 7/7 
CT alone - 6/6 - 1/1 - 4/4 - 1/1 
RT plus CT 12.8 (11.7-13.8) 108/113 14.4 (12.3-16.5) 45/46 12.6 (11.4-13.7) 46/48 9.8 (6.4-13.3) 17/19 
Total 11.0 (9.6-12.4) 168/176 13.9 (12.1-15.8) 61/62 9.7 (7.9-11.5) 77/80 7.7 (4.4-10.8) 30/34 
Legend: CT, alkylating chemotherapy; RT, radiation therapy; MGMT, O6-methylguanine-DNA methyltransferase 
 
 




